샘플 요청 목록

 카트 문의
시장보고서
상품코드
1525405

항염증약 : 시장 인사이트, 역학, 시장 예측(2030년)

Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

항염증약 시장 규모는 2024-2030년의 예측 기간 중 5.73%의 CAGR로 확대할 것으로 예측됩니다. 항염증약의 수요는 주로 천식, 관절염, 만성폐쇄성폐질환(COPD) 등 다양한 만성질환의 유병률 증가로 인해 증가하고 있습니다. 또한 항종양괴사인자(TNF), 인터루킨, 야누스 키나아제 억제제, 항염증 생물학적 제제, 면역 선택적 항염증약(ImSAIDs)에 대한 연구 증가, 자가면역질환의 유병률 증가, 바이오시밀러 개발에 대한 관심 증가, 전 세계 여러 국가에서 약물의 출시 및 승인 등이 2024-2030년의 예측 기간 중 항염증약 시장의 성장에 기여하고 있습니다.

항염증약 시장을 촉진하는 중요한 측면 중 하나는 전 세계에서 만성 통증과 염증의 부담이 증가하고 있다는 점입니다.

European Pain Federation의 데이터(2023년)에 따르면 7억 4,000만 명이 일생에 한 번쯤은 극심한 통증을 경험한 적이 있다고 합니다. 이 중 약 20%는 통증이 3개월 이상 지속되는 만성 통증으로 분류됩니다.

또한 세계보건기구(2023년)에 따르면 요통(LBP) 환자 수는 현재 약 6억 1,900만 명이며, 2050년에는 8억 4,300만 명으로 증가할 것으로 예측했습니다. 항염증약은 경증에서 중증의 통증 치료에 가장 많이 처방되는 약물입니다. 미국 가정의학회는 이부프로펜과 나프록센을 경증에서 중등도 통증 치료의 1차 선택 약물로 권장하고 있습니다. 따라서 이러한 적극적인 추천은 시장 성장을 가속할 것으로 예상됩니다.

또한 천식은 모든 연령대의 사람들에게 영향을 미치는 만성 폐 질환입니다. 천식은 호흡기 주변의 염증과 근육 경화로 인해 호흡 곤란을 유발하여 호흡 곤란을 유발합니다. 세계보건기구(WHO)의 2023년 발표에 따르면 천식은 약 2억 6,200만 명이 앓고 있다고 합니다.

세계의 항염증약 시장에 대해 조사했으며, 시장의 개요와 약제 클래스별, 적응증별, 판매채널별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 항염증약 시장 보고서 서론

제2장 항염증약 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 항염증약 시장의 주요 요인 분석

  • 항염증약 시장 촉진요인
  • 항염증약 시장 억제요인과 과제
  • 항염증약 시장의 기회

제6장 항염증약시장 Porter's Five Forces 분석

제7장 항염증약 시장의 평가

  • 약제 클래스별
  • 적응증별
  • 판매채널별
  • 지역별

제8장 항염증약 시장의 기업과 제품 개요

  • Amgen Inc
  • Sun Pharmaceutical Industries Ltd
  • Johnson & Johnson Services, Inc
  • Pfizer Inc
  • Medical Device Business Services, Inc
  • Novartis AG
  • GSK plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • AstraZeneca
  • Merck & Co., Inc
  • Lilly
  • Bristol-Myers Squibb Company
  • Biogen
  • Aurobindo Pharma
  • Reckitt Benckiser Group PLC.
  • Dr. Reddy's Laboratories Ltd
  • Sanofi
  • Strides Pharma Science Limited
  • Heron Therapeutics, Inc

제9장 KOL 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항과 문의

KSA 24.08.07

Anti-Inflammatory Drugs Market by Drug Class (Anti-Inflammatory Biologics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, and Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, and Others), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing burden of chronic pain and inflammation diseases such as migraine, arthritis, ophthalmic diseases, among others, and the increasing research & developmental activities in the anti-inflammatory drugs market across the globe

The anti-inflammatory drugs market is estimated to advance at a CAGR of 5.73% during the forecast period from 2024 to 2030. The demand for anti-inflammatory drugs is primarily being boosted by the increasing prevalence of various chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and other diseases. Further, the increasing research on anti-tumor necrosis factor (TNF), interleukins, Janus kinase inhibitors, anti-inflammatory biologics, immune selective anti-inflammatory derivatives (ImSAIDs), the rising prevalence of auto-immune diseases, increasing focus on developing biosimilar, drugs launches and approval across the globe, among others are contributing to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024 to 2030.

Anti-Inflammatory Drugs Market Dynamics:

One of the key aspects driving the Anti-Inflammatory Drugs market is the rising burden of chronic pain and inflammation across the globe.

According to data from the European Pain Federation (2023), it was stated that 740 million people experienced an episode of severe pain at some point in their lives. For approximately 20% of these individuals, the pain persists for longer than three months, thereby categorizing it as chronic pain.

Moreover, as per the World Health Organization (2023), there are approximately 619 million cases of lower back pain (LBP) currently and it is projected that the number of LBP cases will rise to 843 million by 2050. Anti-inflammatory drugs are the most commonly prescribed drugs for the treatment of mild to severe pain. The American Academy of Family Physicians recommends the use of ibuprofen and naproxen as the first line of treatment for mild to moderate pain. Thus, such positive recommendations are expected to boost the market growth.

Additionally, asthma is a chronic lung disease affecting people of all ages. It is caused by inflammation and muscle tightening around the airways, which makes it harder to breathe. As per the World Health Organization (WHO) 2023, asthma afflicted about 262 million people.

All the above sources state that the prevalence of chronic pain and inflammatory diseases is increasing across the globe which can be managed or treated using various types of anti-inflammatory drugs such as corticosteroids and NSAIDs.

Lastly, the increasing number of anti-inflammatory drug launches and approvals in the market will aid in increasing its demand in the upcoming years. For instance, in May 2021, Heron Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) approved Zynrelef, an extended-release dual-acting local anesthetic of bupivacaine and meloxicam for pain management.

Also, the leading anti-inflammatory biologics patents have paved the path for biosimilars to enter the market. Due to the rising demand and quicker approval process for biosimilars than for new drugs, several manufacturers have moved their attention to this area. This has grown to be a significant market trend. Adalimumab, infliximab, and etanercept biosimilars are competing against Humira, Remicade, and Enbrel, the three biologics with considerable market revenue potential.

Therefore, all the above-mentioned factors are expected to contribute to the growth of the anti-inflammatory drugs market during the forecast period from 2024 to 2030.

However, side effects associated with drugs, the timeline for stringent regulatory procedures, and others may restrict the anti-inflammatory drugs market growth.

Anti-Inflammatory Drugs Market Segment Analysis:

Anti-Inflammatory Drugs Market by Drug Class (Anti-Inflammatory Biologics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, and Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, and Others), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the anti-inflammatory drugs market, the arthritis category is expected to amass a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches, strategic investments, and other activities by the key players related to the segment will support driving its market during the forecast period.

For instance, as per the Global RA Network 2021, more than 350 million people had arthritis, in 2021, globally. Further, according to the World Health Organization (2021), more than 14 million people had rheumatoid arthritis in 2021 globally.

Thus, the rising prevalence of the different types of arthritis is quite high globally, ultimately leading to the increased demand for arthritis-managing anti-inflammatory drugs.

Non-steroidal anti-inflammatory medicines (NSAIDs), such as diclofenac, ibuprofen, and naproxen, are quite helpful in reducing osteoarthritis pain. Still, they also carry a risk of adverse effects such as stomach upset, cardiovascular issues, blood issues, liver damage, and kidney damage. Thus, the above sources clearly state that the prevalence of different types of arthritis is quite high globally, ultimately leading to the increased demand for arthritis-managing anti-inflammatory drugs.

Further, the increasing product launches and approvals will also create a positive impact on segmental growth. For instance, in January 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI(R) (risankizumab-rzaa), a type of anti-inflammatory drugs for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.

Moreover, various other strategic steps by the key players in the market will help in increasing demand for anti-inflammatory drugs. For example, in January 2021, the U.S. Food and Drug Administration approved a generic version of Pfizer's Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The generic drug is also indicated to treat osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea.

Thus, the above-mentioned factors are likely to propel the demand for arthritis-treating anti-inflammatory drugs, thereby contributing to the growth of the anti-inflammatory drugs market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall anti-inflammatory drugs market:

Among all the regions, North America is estimated to account for the largest share of the anti-inflammatory drugs market in the year 2023. This domination is due to the increasing chronic pain and rising adoption of non-steroidal, anti-inflammatory drugs in headaches, migraine, toothaches, menstrual pain, and others, increasing launch and approvals of drugs by market players, established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drug, high income per capita, rise in patient visits to physicians, and research advancements due to high funding among others will propel the market of anti-inflammatory drugs in North America.

According to the Centre for Disease Control and Prevention (2024), it was stated that in 2022, the age-adjusted prevalence of diagnosed arthritis among adults aged 18 and older was 18.9%. The prevalence was higher among women, at 21.5%, compared to men, at 16.1%. The incidence of arthritis increased with age, starting from 3.6% in adults aged between 18 and 34 and rising significantly to 53.9% in individuals aged 75 and older in the US. Also, by the year 2040, an estimated 78.4 million US adults aged 18 years and older will be diagnosed with arthritis.

The data provided by the Arthritis Society Canada, 2021, stated that in 2021, nearly 6 million people were living with arthritis in Canada. The number is expected to rise to 9 million by 2040.

According to the American Headache Society (2022), stated that 37 million people were living with migraine in the US. This substantial prevalence of migraines highlights a significant and growing market for nonsteroidal anti-inflammatory drugs. Additionally, with the growing awareness and diagnosis of migraines, healthcare providers may prescribe NSAIDs more frequently as part of a comprehensive pain management plan. This expanding market presents an opportunity for further research and development of more advanced anti-inflammatory drug formulations.

Thus, the rising prevalence of chronic pain and inflammation-related disorders such as migraine, arthritis, and others will propel the demand for anti-inflammatory drugs during the forecast period.

Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For example, in December 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for XELJANZ(R) / XELJANZ(R) XR (tofacitinib), an anti-inflammatory drug for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Moreover, the market players in the country are continuously focusing on the development of novel drugs to tackle these indications using NSAIDs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in March 2024, Endo International plc a leading key player in the US announced, that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North America anti-inflammatory drugs market.

Anti-Inflammatory Drugs Market key players:

Some of the key market players operating in the Anti-Inflammatory Drugs Market include Amgen Inc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Pfizer Inc, Medical Device Business Services, Inc, Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd, AbbVie Inc, AstraZeneca, Merck & Co., Inc, Lilly, Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC, Dr. Reddy's Laboratories Ltd, Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc, and others.

Recent Developmental Activities in the Anti-Inflammatory Drugs Market:

  • In August 2022, Strides Pharma Global Pte Ltd received approval from the US health regulator for generic naproxen sodium soft gel capsules, used to treat pain or inflammation.
  • In August 2021, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA.
  • In August 2021, Dr. Reddy's Laboratories Ltd, announced the re-launch of over the counter (OTC) Naproxen Sodium Tablets USP, 220 mg, in the US market, as approved by the US Food and Drug Administration (USFDA).

Key Takeaways from the Anti-Inflammatory Drugs Market Report Study

  • Market size analysis for current anti-inflammatory drugs market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the anti-inflammatory drugs market.
  • Various opportunities available for the other competitors in the anti-inflammatory drugs market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current anti-inflammatory drugs market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for anti-inflammatory drugs market growth in the coming future?

Target audience who can be benefited from this Anti-Inflammatory Drugs Market Report Study

  • Anti-inflammatory drug providers
  • Research organizations and consulting companies
  • Anti-inflammatory drugs-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in anti-inflammatory drugs
  • Various manufacturers want to know more about the anti-inflammatory drugs market and the latest developments in the anti-inflammatory drugs market.

Frequently Asked Questions for the Anti-Inflammatory Drugs Market:

1. What is anti-inflammatory drugs market?

The anti-inflammatory drugs are a group of drugs that aid in reducing inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation.

2. What is the market for anti-inflammatory drugs market?

The anti-inflammatory drugs market is estimated to advance at a CAGR of 5.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the anti-inflammatory drugs market?

The anti-inflammatory drugs market is witnessing positive market growth owing to the growing burden of chronic pain and inflammation such as arthritis, and migraine, among others, the increasing geriatric population base prone to chronic pain, the emergence of anti-inflammatory biologics, and increasing drug launches and approvals, among others, thereby contribute to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the anti-inflammatory drugs market?

Some of the key market players operating in the anti-inflammatory drug market include Amgen Inc., Sun Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Medical Device Business Services, Inc, Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca, Merck & Co., Inc, Lilly, Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC, Dr. Reddy's Laboratories Ltd, Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc, and others.

5. Which region has the highest share in the anti-inflammatory drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the Anti-Inflammatory Drugs market. This can be ascribed to the increasing demand for anti-inflammatory biologics, government support for the launch of biosimilars, significant research investment, increased, presence of favorable regulatory authorities, rising product launch and approvals, and the presence of key players in the region, among others will positively impact the North America anti-inflammatory drugs market during the forecast period from 2024 to 2030.

Table of Contents

1. Anti-Inflammatory Drugs Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Anti-Inflammatory Drugs Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Anti-Inflammatory Drugs Market Key Factors Analysis

  • 5.1. Anti-Inflammatory Drugs Market Drivers
    • 5.1.1. The growing burden of chronic pain and inflammation
    • 5.1.2. Increasing geriatric population base prone to chronic pain
    • 5.1.3. Rising adoption of anti-inflammatory biologics
  • 5.2. Anti-Inflammatory Drugs Market Restraints and Challenges
    • 5.2.1. Side effects associated with drugs
    • 5.2.2. Stringent regulatory procedures
  • 5.3. Anti-Inflammatory Drugs Market Opportunities
    • 5.3.1. Availability of a robust product portfolio
    • 5.3.2. Increasing focus on developing biosimilars by key pharmaceutical companies

6. Anti-Inflammatory Drugs Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Anti-Inflammatory Drugs Market Assessment

  • 7.1. By Drug Class
    • 7.1.1. Anti-Inflammatory Biologics
    • 7.1.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • 7.1.3. Immune-selective anti-inflammatory derivative (ImSAID)
    • 7.1.4. Corticosteroids
    • 7.1.5. Others
  • 7.2. By Indication
    • 7.2.1. Arthritis
    • 7.2.2. Asthma
    • 7.2.3. Inflammatory bowel disease (IBD)
    • 7.2.4. Chronic obstructive pulmonary disease (COPD)
    • 7.2.5. Multiple Sclerosis
    • 7.2.6. Others
  • 7.3. By Sales Channel
    • 7.3.1. Prescription
    • 7.3.2. Over the Counter (OTC)
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.1.2. Canada Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.1.3. Mexico Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.2.2. Germany Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.2.4. Italy Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.2.5. Spain Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.3.2. Japan Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.3.3. India Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.3.4. Australia Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.3.5. South Korea Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia-Pacific Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.4.2. Africa Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
      • 7.4.4.3. South America Anti-Inflammatory Drugs Market Size in USD million (2021-2030)

8. Anti-Inflammatory Drugs Market Company and Product Profiles

  • 8.1. Amgen Inc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Sun Pharmaceutical Industries Ltd
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Johnson & Johnson Services, Inc
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Pfizer Inc
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Medical Device Business Services, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Novartis AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. GSK plc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. F. Hoffmann-La Roche Ltd
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. AbbVie Inc
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. AstraZeneca
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Merck & Co., Inc
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Lilly
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Bristol-Myers Squibb Company
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Biogen
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Aurobindo Pharma
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Reckitt Benckiser Group PLC.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Dr. Reddy's Laboratories Ltd
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Sanofi
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Strides Pharma Science Limited
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Heron Therapeutics, Inc
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제